Margin growth masks volume declines; one-time gains inflate EBITDA

Delivered revenue 2,387 Cr, 42.5% YoY growth

Delivered PAT 155 Cr, 258% YoY growth

If gains are ₹50–60 Cr, core EBITDA ~₹325–335 Cr; quality compressed

12% overall volume decline QoQ is material softness vs delivered revenue +8.2% QoQ

Impact quantified but redirection efficacy unclear; offset sales loss with price, not new volume

15% revenue exposure to Middle East fell to 2% due to geopolitical crisis. Diversion to other markets limits pricing power and margin recovery.

Labour shortage (LPG issue), elections, monsoon triggered delays. MPP expected Aug '26 now; 5 chemistry blocks phased FY27–29 vs originally FY27. Impacts FY28 EBITDA ramp.

Major expansion programs nearing completion; pivot to high-growth niche projects. FY27 ₹700–800 Cr capex will tail as Zone IV finishes.

3–5 new products in pipeline across fuel additives; 1–2 years to scale. Strategy to reduce single-product risk; execution timeline uncertain.

China VAT suspension created pricing tailwind. Management notes improvement 'last quarter' and expects sustained benefit as global chemical overcapacity rationalises post-2028.

JVs (Augene, RESL) expected on time. 5 chemistry blocks delayed but phasing into FY27–29. Will update once units commission and ramp visible.

Combined ₹50–60 Cr possible. Difficult to quantify precisely due to monthly RM price volatility (April high, May-June correction, June-July restart). Timing of purchase vs placement supported EBITDA.

Market development phase still ongoing. Portfolio now balanced across U.S., Africa, Europe, Middle East, India. Can move volumes regionally. When Middle East opens, will add capacity utilization, not shift volume. Confidence high on demand side given strong gasoline-naphtha cracks.

Significant competition already exists. Strategy: new differentiated products, global supply chain, unique distribution. Cost leadership guaranteed (top decile). Multiple levers beyond price.

Maintaining ₹300–400 Cr range for now. Will refine once Q2 ramp complete and stabilised. Expected 1–2 years to decent utilisation. PAT consolidation starts Q2, meaningful difference 2–4 quarters out.

Two factors: RM inflation (cyclical) and NCB chain China VAT removal (structural). Some reversal on RM, but VAT element may sustain. Portfolio-specific dynamics differ.

FX gain is accounting/volatility artifact. In future, if pricing stable throughout quarter, underlying business potential will show. Volume recovery should compensate for gain loss. Trajectory on track.

59% exports for the quarter. Exports expected up in Q2. Supply chain changing to longer-destination geographies (U.S., Americas). Revenue recognition timing linked to inco terms (DAP). But underlying volume trajectory solid.

Strategy changed 1.5 years ago: 5 chemistry blocks now flexible (not just chlorotoluene). 97% equipment erected, 85% piping done. Challenge: manpower for piping/insulation. March–May labour shortage (LPG, elections, monsoon). Back to full capacity now. Commissioning FY27.

Two dominant end markets: coatings (larger, India-focused) and dyes. Profitability expected higher margin profile vs current portfolio. Exposure to different end market helpful for diversification.

Market remains very strong globally, linked to end-market (gasoline/naphtha cracks). When Middle East opens, goal is to increase capacity utilisation, not shift volume. Pulling from all geographies to boost utilisation.

Spreads averaged $15–18/bbl globally, healthy. Will not name products at this stage. 3–5 products in pipeline. Broadening from MMA to multiproduct portfolio over 12 months.

Risk always remains in crude-linked business. Mitigation: 7–15 days domestic RM inventory, 1–1.5 months import inventory. Strategies: forward booking, hedging. Risk actively managed but will always exist.

Different chains have different stories. NCB recovered in last quarter (China VAT impact). DCB always decent margins. NT suppressed, working on rebalancing strategies. PDA weak (tech disadvantage). Objective: expand volume and margin across all chains.

Target customers identified, pilot qualification done in most cases. Commercial batch requalification required post-commissioning. By FY28, 25–30 products target. FY27, 5–10 products expected.

Assets capable of more volume. Minor debottlenecking being evaluated. Dominant end market: pharmaceuticals (paracetamol). Watching Indian consumption potential. Aggressive once domestic demand justifies capex.

Difficult to predict. Chemical industry turbulent 3–4 years post-COVID. Global rationalization ongoing (Europe, Northeast Asia, China slowdown). If continues, post-2028/2029 could see demand pickup, capacity tightness, margin restructuring. Hypothesis—need 2–3 years to validate.

Not far away. Given ±15–20% monthly volatility, difficult to hazard guess. Volume growth could compensate for lost inventory gains. Near-term quarter outlook: volume gain offsets gain loss.

Augene EBITDA included in ₹1,800 Cr guidance (expected to contribute by then). Re Aarti not expected to contribute meaningfully before FY27–28. Reporting treatment to be determined.

Ramping up as we speak. Might reach high utilisation levels this quarter. (Note: implies near-term pickup expected.)

Gross margin at quarterly level not reflective of steady-state. EBITDA % on track. Multiple factors: RM purchase timing, product placement timing, FX volatility within quarter, freight volatility, lower volume/higher opex in some cases. Not a structural decline.

Fuel additives basket has seasonal weakness in winter (Oct–Dec). Cracks step down, demand softens. Prepared for winter downturn. Mitigation strategies for lean season under evaluation. Some seasonality expected.

Limited Middle East exposure in polymers. Q4 had bulk shipments to U.S. customers; Q1 shipments low as a result. Recovery expected Q2. Year-on-year growth still expected.

Well-balanced across geographies. Not tilted to one. QoQ volatility (one geo picks up significant share), but year-average balanced. Will not give exact split.

No direct margin impact. Impacts accounting: many sales on DAP terms, 2–3 month voyage time delays revenue recognition. Accounting artifact, not economic profit issue.

Did not say EBITDA run rate maintained. Two factors: volume gain (confident and visible) and pricing/inventory (macro-dependent, uncertain). Geopolitical settlement timing and pricing change speed will determine margin path.

Will not give number. Overall fuel additive market in millions of tons. Early market development journey; phases of customer adoption ongoing. Upper-side potential high but unrealistic to quantify. Trade flows dynamic.

Recently expanded to 360 KTPA. Capacity for overall fuel additives block (not single product). Will stabilise utilisation over 12 months, then decide on further expansion. No restrictions on future capacity growth.

Most end markets showing steady demand. Agro stable, polymers strong (EVs, automotive), pharma robust, dyes/pigments soft. Selection based on ability to deliver customer value and return on capital. Forward-looking molecules (battery, defense) driven by differentiation and scale potential.

Volatility in Q4 and Q1 on currencies. INR92–97 range in quarter. Sourced imported material high, rupee appreciated in April, squared up at lower rate (gain). Exports initially at lower rates vs current. Operational element with mark-to-market. Going forward, difficult to commit to gain/loss due to macro factors.

Products part of strategic focus. Most contracts have ethylene price pass-through (quarterly or monthly). Margin profile secured. Volatility near-term but long-term robust. Closures in Japan/Korea don't impact India/China/Europe production zones for these products.

Do not name customer. Long-term contract announced last quarter. In project execution phase. Civil/building work ongoing. Commissioning expected Sept–Oct 2027. (Note: project execution lagging slightly given call date was July 31, 2026.)

Management deferred on specific FY27 revenue forecasts. Implied growth from EBITDA targets suggests mid-teens growth assumed.

Management noted one-time gains (₹50–60 Cr) temporary. Underlying EBITDA margin ~13.6% (normalised). Expansion possible if volumes ramp and RM stabilises.

At current burn rate (₹180 Cr per quarter), ₹700–800 Cr achievable over full year. Major programs (Zone IV, Augene, RESL, MPP) progressing.

Once Zone IV phases complete, pivot to high-growth, high-return niche projects. Capital efficiency improvement expected.

Zone IV 5 chemistry blocks delayed by labour shortage and geopolitical issues. March–May labour constraints (LPG shortage, elections, monsoon). Phased commissioning FY27–FY29 vs originally FY27. MPP Aug 2026 timeline tight.

Middle East geopolitical tension temporarily halted exports to region. 15% of revenues to West Asia fell to 2% in Q1. Volumes redirected to U.S., Africa, Europe, but at lower margins. Duration of crisis uncertain; recovery timeline unknown.

Despite 42.5% YoY revenue growth (driven by raw material pass-through), absolute volumes contracted sharply QoQ. Energy segment hit by West Asia disruption; non-energy by customer purchasing delays (high RM environment) and bulk Q4 shipments pulling forward.

EBITDA ₹385 Cr boosted by ₹50–60 Cr inventory gains and forex benefits from rupee volatility (INR92–97 range in quarter). Strip gains and core EBITDA ~₹325–335 Cr, well below stated ₹385 Cr. Gains temporary and non-recurring.

Fuel additives market ('market development phase') now seeing competitor entry from Indian and Chinese players. Management maintains market leadership but competitive pressure mounting. Differentiation via products, supply chain, cost structure required but not assured.

Higher feedstock prices and increased export volumes expanded working capital requirements in Q1. Debt levels and finance costs rose to support WC needs. Deleveraging target at risk if WC inflation persists.

Augene JV (amines) expected to commission Q2 FY27 with ₹300–400 Cr steady-state revenue. RESL (plastic recycling) H2 FY27. FY28 EBITDA ₹1,800 Cr includes Augene contribution. Execution delays, low ramp-up, or market softer-than-expected could miss targets.